Melanoma and Skin Cancer
Crossing Therapeutic Boundaries: Molecular Profiling May Help Move Noncancer Drugs Into Oncology Settings
One of the most striking changes in our understanding of the fundamental biology of malignant disease has been the observation that “driver” molecular abnormalities may frequently cross major histologic barriers.
Most Popular Right Now
CME activity worth 1.0 CME credits by Keith T. Flaherty, MD, Jeffrey S. Weber, MD, PhD, and Jedd D. Wolchok, MD, PhD.